Meeting
2022 ASCO Annual Meeting
A pan-cancer analysis of P21 activated kinase (PAK) family genes as potential biomarkers for immune checkpoint therapy.
Authors
Sun Gang
The Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang Cancer Center, Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region, Urumqi, China
Sun Gang , Wenjia Guo , Lei Qiao , Tonghui Sun , Yuan Tan , Qin Zhang , Qianqian Duan , Tingting Sun , Chuang Qi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2614)
DOI
10.1200/JCO.2022.40.16_suppl.2614
Abstract #
2614
Poster Bd #
269
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A pan-cancer analysis of MUC family genes as potential biomarkers for immune checkpoint therapy.
First Author: Yang Li
Poster
2021 ASCO Annual Meeting
Relationship between DICER1 mutations and immunotherapy biomarkers in solid tumors.
First Author: Jie Gao
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
First Author: Shridar Ganesan
Poster
2021 ASCO Annual Meeting
Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.
First Author: Shengli Yang